BG108537A - Единична доза азитромицин - Google Patents
Единична доза азитромицин Download PDFInfo
- Publication number
- BG108537A BG108537A BG108537A BG10853704A BG108537A BG 108537 A BG108537 A BG 108537A BG 108537 A BG108537 A BG 108537A BG 10853704 A BG10853704 A BG 10853704A BG 108537 A BG108537 A BG 108537A
- Authority
- BG
- Bulgaria
- Prior art keywords
- dose
- azithromycin
- use according
- treatment
- single dose
- Prior art date
Links
- 229960004099 azithromycin Drugs 0.000 title claims abstract description 44
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 title claims abstract description 44
- 206010057190 Respiratory tract infections Diseases 0.000 claims abstract description 16
- 238000011282 treatment Methods 0.000 claims description 23
- 208000022760 infectious otitis media Diseases 0.000 claims description 17
- 230000037396 body weight Effects 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 description 16
- 241000606768 Haemophilus influenzae Species 0.000 description 8
- 206010033078 Otitis media Diseases 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 241000588655 Moraxella catarrhalis Species 0.000 description 4
- 210000000959 ear middle Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 241000193996 Streptococcus pyogenes Species 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000011556 gerbil model Methods 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 210000003454 tympanic membrane Anatomy 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 101150076489 B gene Proteins 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 229930006677 Erythromycin A Natural products 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000754835 Sapovirus isolates Species 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 208000032625 disorder of ear Diseases 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31386701P | 2001-08-21 | 2001-08-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG108537A true BG108537A (bg) | 2005-02-28 |
Family
ID=23217490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG108537A BG108537A (bg) | 2001-08-21 | 2004-01-21 | Единична доза азитромицин |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US20030148964A1 (cs) |
| EP (1) | EP1418924A2 (cs) |
| JP (1) | JP2005501862A (cs) |
| KR (1) | KR20040032942A (cs) |
| AP (1) | AP1729A (cs) |
| BG (1) | BG108537A (cs) |
| BR (1) | BR0211830A (cs) |
| CA (1) | CA2458135A1 (cs) |
| CZ (1) | CZ2004232A3 (cs) |
| EA (1) | EA200400214A1 (cs) |
| EC (1) | ECSP044985A (cs) |
| GE (1) | GEP20063812B (cs) |
| HR (1) | HRP20040163A2 (cs) |
| HU (1) | HUP0401332A2 (cs) |
| IL (1) | IL159585A0 (cs) |
| IS (1) | IS7092A (cs) |
| MA (1) | MA27059A1 (cs) |
| MX (1) | MXPA04001605A (cs) |
| OA (1) | OA12845A (cs) |
| PL (1) | PL367888A1 (cs) |
| SK (1) | SK1012004A3 (cs) |
| TN (1) | TNSN04035A1 (cs) |
| WO (1) | WO2003018031A2 (cs) |
| YU (1) | YU8804A (cs) |
| ZA (1) | ZA200400804B (cs) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1648473B1 (en) * | 2003-07-24 | 2009-01-28 | PLIVA HRVATSKA d.o.o. | Single dose fast dissolving azithromycin |
| EP1691786A1 (en) | 2003-12-04 | 2006-08-23 | Pfizer Products Inc. | Multiparticulate compositions with improved stability |
| WO2005053656A1 (en) | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride |
| US6984403B2 (en) | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
| PL1691787T3 (pl) | 2003-12-04 | 2008-11-28 | Pfizer Prod Inc | Sposób wytwarzania farmaceutycznych systemów wielocząstkowych |
| US20060116336A1 (en) * | 2004-03-17 | 2006-06-01 | American Pharmaceutical Partners, Inc. | Lyophilized azithromycin formulation |
| US7468428B2 (en) | 2004-03-17 | 2008-12-23 | App Pharmaceuticals, Llc | Lyophilized azithromycin formulation |
| ES2594368T3 (es) | 2005-12-08 | 2016-12-19 | Insmed Incorporated | Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares |
| US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
| US20090005326A1 (en) * | 2007-06-26 | 2009-01-01 | Idexx Laboratories, Inc. | Single dose roxithromycin |
| US20090197956A1 (en) * | 2008-02-04 | 2009-08-06 | Arbor Pharmaceuticals, Inc. | Treatment of acute otitis media with xylitol and n-acetylcysteine |
| WO2009114810A2 (en) * | 2008-03-14 | 2009-09-17 | The Florida International Uinversity Board Of Trustees | Use of ellagitannins as inhibitors of bacterial quorum sensing |
| WO2012170356A1 (en) | 2011-06-04 | 2012-12-13 | Rochester General Hospital Research Institute | Compositions and methods related to p6 of haemophilus influenzae |
| JP6529438B2 (ja) | 2012-11-29 | 2019-06-12 | インスメッド インコーポレイテッド | 安定化されたバンコマイシン処方物 |
| CN106535877A (zh) | 2014-05-15 | 2017-03-22 | 英斯梅德股份有限公司 | 用于治疗肺部非结核性分枝杆菌感染的方法 |
| JP7460534B2 (ja) | 2018-03-30 | 2024-04-02 | インスメッド インコーポレイテッド | リポソーム医薬品の連続製造方法 |
| WO2021163451A1 (en) * | 2020-02-14 | 2021-08-19 | Asklepios Biopharmaceutical, Inc. | Method of treating gene therapy associated toxicity with antibiotics |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US53264A (en) * | 1866-03-20 | Improved ditching-machine | ||
| YU43116B (en) | 1979-04-02 | 1989-04-30 | Pliva Pharm & Chem Works | Process for preparing 11-aza-4-o-cladinosyl-6-o-desosaminyl-15-ethyl-7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl-oxacyclopentadecane-2-one(11-aza-10-deox |
| SI8110592A8 (en) | 1981-03-06 | 1996-06-30 | Pliva Pharm & Chem Works | Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof |
| US4474768A (en) | 1982-07-19 | 1984-10-02 | Pfizer Inc. | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor |
| UA27040C2 (uk) | 1987-07-09 | 2000-02-28 | Пфайзер Інк. | Кристалічhий дигідрат азитроміциhу та спосіб одержаhhя кристалічhого дигідрату азитроміциhу |
| WO1989002271A1 (en) | 1987-09-10 | 1989-03-23 | Pfizer | Azithromycin and derivatives as antiprotozoal agents |
| YU45590A (sh) | 1990-03-07 | 1992-07-20 | PLIVA FARMACEVTSKA, KEMIJSKA, PREHRAMBENA I KOZMETIČKA INDUSTRIJA s.p.o. | Novi kompleksi odnosno helati antibiotika s dvovalentnim i/ili trovalentnim metalima i postupci za njihovo dobijanje |
| TW271400B (cs) | 1992-07-30 | 1996-03-01 | Pfizer | |
| DE69403963T2 (de) | 1993-05-19 | 1997-11-20 | Pfizer | Zwischenprodukt für azithromycin |
| US5605889A (en) | 1994-04-29 | 1997-02-25 | Pfizer Inc. | Method of administering azithromycin |
| EP0758244B2 (en) | 1994-05-06 | 2008-02-13 | Pfizer Inc. | Controlled-release dosage forms of azithromycin |
| HRP980189B1 (en) * | 1998-04-06 | 2004-04-30 | Pliva Pharm & Chem Works | Novel 15-membered lactams ketolides |
| US6239113B1 (en) * | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
| US20040053264A1 (en) * | 2002-02-01 | 2004-03-18 | Park Sung Sup | Clinical panel assay using DNA chips |
-
2002
- 2002-07-31 CZ CZ2004232A patent/CZ2004232A3/cs unknown
- 2002-07-31 HU HU0401332A patent/HUP0401332A2/hu unknown
- 2002-07-31 AP APAP/P/2004/002968A patent/AP1729A/en active
- 2002-07-31 HR HR20040163A patent/HRP20040163A2/xx not_active Application Discontinuation
- 2002-07-31 YU YU8804A patent/YU8804A/sh unknown
- 2002-07-31 JP JP2003522549A patent/JP2005501862A/ja active Pending
- 2002-07-31 MX MXPA04001605A patent/MXPA04001605A/es active IP Right Grant
- 2002-07-31 SK SK101-2004A patent/SK1012004A3/sk not_active Application Discontinuation
- 2002-07-31 IL IL15958502A patent/IL159585A0/xx unknown
- 2002-07-31 EA EA200400214A patent/EA200400214A1/ru unknown
- 2002-07-31 EP EP02753170A patent/EP1418924A2/en not_active Withdrawn
- 2002-07-31 WO PCT/IB2002/003076 patent/WO2003018031A2/en not_active Application Discontinuation
- 2002-07-31 BR BR0211830-0A patent/BR0211830A/pt not_active IP Right Cessation
- 2002-07-31 GE GE5411A patent/GEP20063812B/en unknown
- 2002-07-31 KR KR10-2004-7002492A patent/KR20040032942A/ko not_active Ceased
- 2002-07-31 OA OA1200400048A patent/OA12845A/en unknown
- 2002-07-31 CA CA002458135A patent/CA2458135A1/en not_active Abandoned
- 2002-07-31 PL PL02367888A patent/PL367888A1/xx not_active Application Discontinuation
- 2002-08-21 US US10/224,903 patent/US20030148964A1/en not_active Abandoned
-
2003
- 2003-07-25 US US10/628,102 patent/US6987093B2/en not_active Expired - Fee Related
- 2003-12-23 IS IS7092A patent/IS7092A/is unknown
-
2004
- 2004-01-21 BG BG108537A patent/BG108537A/bg unknown
- 2004-01-30 ZA ZA200400804A patent/ZA200400804B/en unknown
- 2004-02-11 MA MA27523A patent/MA27059A1/fr unknown
- 2004-02-20 EC EC2004004985A patent/ECSP044985A/es unknown
- 2004-02-20 TN TNP2004000035A patent/TNSN04035A1/fr unknown
-
2005
- 2005-06-29 US US11/172,012 patent/US7067493B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20040032942A (ko) | 2004-04-17 |
| US20030148964A1 (en) | 2003-08-07 |
| JP2005501862A (ja) | 2005-01-20 |
| PL367888A1 (en) | 2005-03-07 |
| OA12845A (en) | 2006-09-15 |
| HUP0401332A2 (hu) | 2004-11-29 |
| US6987093B2 (en) | 2006-01-17 |
| EA200400214A1 (ru) | 2004-06-24 |
| CA2458135A1 (en) | 2003-03-06 |
| ECSP044985A (es) | 2004-04-28 |
| IS7092A (is) | 2003-12-23 |
| HRP20040163A2 (en) | 2005-02-28 |
| IL159585A0 (en) | 2004-06-01 |
| US7067493B2 (en) | 2006-06-27 |
| EP1418924A2 (en) | 2004-05-19 |
| YU8804A (sh) | 2006-08-17 |
| MA27059A1 (fr) | 2004-12-20 |
| AP2004002968A0 (en) | 2004-03-31 |
| GEP20063812B (en) | 2006-05-10 |
| WO2003018031A3 (en) | 2003-10-02 |
| TNSN04035A1 (fr) | 2006-06-01 |
| ZA200400804B (en) | 2005-05-03 |
| AP1729A (en) | 2007-03-26 |
| CZ2004232A3 (cs) | 2005-10-12 |
| US20040023898A1 (en) | 2004-02-05 |
| MXPA04001605A (es) | 2004-07-08 |
| BR0211830A (pt) | 2004-09-08 |
| WO2003018031A2 (en) | 2003-03-06 |
| US20050250712A1 (en) | 2005-11-10 |
| SK1012004A3 (sk) | 2005-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG108537A (bg) | Единична доза азитромицин | |
| McCracken | The rate of bacteriologic response to antimicrobial therapy in neonatal meningitis | |
| Planet et al. | Revisiting bacterial interference in the age of methicillin-resistant staphylococcus aureus: insights into staphylococcus aureus carriage, pathogenicity and potential control | |
| Marchi | Comparative efficacy and tolerability of clarithromycin and amoxycillin in the treatment of out-patients with acute maxillary sinusitis | |
| Vidal et al. | Prophylactic inhibition of colonization by Streptococcus pneumoniae with the secondary bile acid metabolite deoxycholic acid | |
| Marshak et al. | Recurrent pneumococcal otitis media in the chinchilla: a longitudinal study | |
| McLinn | Double blind and open label studies of azithromycin in the management of acute otitis media in children: a review | |
| Smilack et al. | Mycoplasma pneumoniae pneumonia and clindamycin therapy: failure to demonstrate efficacy | |
| McCarty | A multicenter, open label trial of azithromycin for the treatment of children with acute otitis media | |
| Lari et al. | Comparison of cefuroxime and co-amoxiclav in the treatment of acute sinusitis in a sample of the Iranian population | |
| Alper et al. | Efficacy of clarithromycin treatment of acute otitis media caused by infection with penicillin-susceptible,-intermediate, and-resistant Streptococcus pneumoniae in the chinchilla | |
| Bentley et al. | Lincomycin in the treatment of penicillin-resistant staphylococcal infections in children | |
| AU2002313574A1 (en) | Single dose azithromycin for treating respiratory infections | |
| Barlow et al. | Infectious diseases and tropical medicine | |
| US20250120929A1 (en) | Method of treating virus-associated infection using acetaminophen | |
| CN103458681A (zh) | 用于预防感染、降低感染的严重性、及治疗感染的胸腺素α肽 | |
| Ruiz-Bedoya et al. | 191. High-Dose Rifampin-containing Regimens for the Treatment of TB Meningitis | |
| Flume | A role for aerosolized antibiotics | |
| RU2180532C2 (ru) | Способ лечения папилломатоза | |
| Shimizu et al. | The haemodialysis patient who developed acute respiratory distress syndrome after a trip to a hot spring spa. | |
| Mattos Filho et al. | Effect of betamethasone and diclofenac sodium on serum and tissue concentration of amoxicillin: in vivo study in rats | |
| Dandekar et al. | Assessment of the efficacy of telithromycin simulating human exposures against S. pneumoniae with ribosomal mutations in a murine pneumonia model | |
| Golhar et al. | CORONA VIRUS2019: INTRODUCTION AND ITS TREATMENTS | |
| RU2257223C2 (ru) | Способ санации респираторного тракта бактерионосителей | |
| Paul et al. | Diphtheria in a 13 year old adolescent girl: management challenges |